Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2018 Nov 10. pii: S1083-8791(18)30698-0. doi: 10.1016/j.bbmt.2018.11.004. [Epub ahead of print]

PMID:
30423480
2.

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors.

Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, Horowitz MM, Switzer GE, Confer DL, Shaw BE.

Haematologica. 2018 Oct 31. pii: haematol.2018.200121. doi: 10.3324/haematol.2018.200121. [Epub ahead of print]

3.

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, Omel JL, Rainey JM, Rebulla P, Rowley SD, Troner MB, Anderson KC.

J Clin Oncol. 2018 Jan 20;36(3):283-299. doi: 10.1200/JCO.2017.76.1734. Epub 2017 Nov 28.

PMID:
29182495
4.

Oxidative Stress Contributes to Status Epilepticus Associated Mortality.

Pearson-Smith JN, Liang LP, Rowley SD, Day BJ, Patel M.

Neurochem Res. 2017 Jul;42(7):2024-2032. doi: 10.1007/s11064-017-2273-1. Epub 2017 May 2.

5.

Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study.

Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, Horowitz MM, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):165-171. doi: 10.1016/j.bbmt.2016.10.008. Epub 2016 Oct 14.

6.

A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Richter J, Skarbnik AP, Pecora A, Siegel DS.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2165-2171. doi: 10.1016/j.bbmt.2016.08.017. Epub 2016 Aug 31.

7.

Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.

Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, Vesole DH, Adler-Brecher B, Kim D, Donato ML.

Biol Blood Marrow Transplant. 2016 Nov;22(11):2047-2055. doi: 10.1016/j.bbmt.2016.08.003. Epub 2016 Aug 10.

8.

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S.

Bone Marrow Transplant. 2017 Jan;52(1):59-65. doi: 10.1038/bmt.2016.188. Epub 2016 Jul 18.

9.

Cross-sectional study of patient-reported neurobehavioral problems following hematopoietic stem cell transplant and health-related quality of life.

Wu LM, Austin J, Valdimarsdottir H, Isola L, Rowley SD, Diefenbach MA, Cammarata M, Redd WH, Rini C.

Psychooncology. 2014 Dec;23(12):1406-14. doi: 10.1002/pon.3554. Epub 2014 May 21.

PMID:
24846770
10.

The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.

Donato ML, Siegel DS, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, Baker M, Goldberg SL, Mato A, Goy A, Rowley SD.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1211-6. doi: 10.1016/j.bbmt.2014.04.027. Epub 2014 May 2.

11.

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.

Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A.

Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25.

12.

CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.

Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Momméja-Marin H, Boeckh M; CMX001-201 Clinical Study Group.

N Engl J Med. 2013 Sep 26;369(13):1227-36. doi: 10.1056/NEJMoa1303688.

13.

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-2013-02-486324. Epub 2013 Apr 22.

14.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network.

N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.

15.

Economic survivorship stress is associated with poor health-related quality of life among distressed survivors of hematopoietic stem cell transplantation.

Hamilton JG, Wu LM, Austin JE, Valdimarsdottir H, Basmajian K, Vu A, Rowley SD, Isola L, Redd WH, Rini C.

Psychooncology. 2013 Apr;22(4):911-21. doi: 10.1002/pon.3091. Epub 2012 May 18.

16.

Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease.

Martin PJ, Furlong T, Rowley SD, Pergam SA, Lloid M, Schubert MM, Horgan KJ, Storer BE.

Biol Blood Marrow Transplant. 2012 Jun;18(6):922-9. doi: 10.1016/j.bbmt.2011.11.010. Epub 2011 Nov 9.

17.

Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.

Leukemia. 2012 Apr;26(4):633-43. doi: 10.1038/leu.2011.254. Epub 2011 Oct 18.

18.

Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation.

Rowley SD, Donato ML, Bhattacharyya P.

Bone Marrow Transplant. 2011 Sep;46(9):1167-85. doi: 10.1038/bmt.2011.135. Review.

PMID:
21897398
19.

Ephedrine decreases vesicular monoamine transporter-2 function.

Ellis JD, German CL, Birdsall E, Hanson JE, Crosby MA, Rowley SD, Sawada NA, West JN, Hanson GR, Fleckenstein AE.

Synapse. 2011 May;65(5):449-51. doi: 10.1002/syn.20896. No abstract available.

20.

Generic immunosuppressants in hematopoietic cell transplantation.

Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C; American Society of Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2011 Mar;17(3):285-90. doi: 10.1016/j.bbmt.2010.11.006. Epub 2010 Nov 16. No abstract available.

21.

Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Carpenter PA, Couriel DR, Flowers ME, Gupta V, Hsu JW, Jagasia M, Kitko CL, Maziarz RT, Rowley SD, Shaughnessy PJ, van Besien K, Weisdorf D, Lee SJ.

Biol Blood Marrow Transplant. 2011 Jan;17(1):124-32. doi: 10.1016/j.bbmt.2010.06.018. Epub 2010 Jun 30.

22.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D.

Blood. 2009 May 21;113(21):5074-82. doi: 10.1182/blood-2009-02-202937. Epub 2009 Mar 6.

23.

Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.

Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.

Synapse. 2009 Feb;63(2):147-51. doi: 10.1002/syn.20580.

24.

Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.

Volz TJ, Farnsworth SJ, Rowley SD, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2008 Oct;327(1):161-7. doi: 10.1124/jpet.108.139386. Epub 2008 Jun 30.

25.

Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation.

Friedman TM, Goldgirsh K, Berger SA, Zilberberg J, Filicko-O'Hara J, Flomenberg N, Donato M, Rowley SD, Korngold R.

Blood. 2008 Oct 15;112(8):3517-25. doi: 10.1182/blood-2008-03-145391. Epub 2008 Jun 9.

26.

Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.

Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-8. Epub 2007 Oct 10.

27.

Implications of staffing ratios and workload limitations on healthcare-associated infections and the quality of patient care.

Assadian O, Toma CD, Rowley SD.

Crit Care Med. 2007 Jan;35(1):296-8. Review. No abstract available.

PMID:
17197771
28.

Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.

Friedman TM, Azhipa O, Zilberberg J, Tkachuk Y, Hsu JW, Rowley SD, Goldberg SL, Korngold R, Pecora AL, Preti RA.

Biol Blood Marrow Transplant. 2006 Oct;12(10):1092-5. No abstract available.

29.

The journey of a teaching hospital to become a learning organisation.

Rowley SD.

Aust Health Rev. 2006 May;30(2):232-40.

PMID:
16646772
30.

Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy.

Bisaccia E, Palangio M, Gonzalez J, Adler KR, Scarborough R, Goldberg SL, Rowley SD.

J Clin Apher. 2006 Oct;21(3):181-7.

PMID:
16607632
31.

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G.

Blood. 2005 Sep 1;106(5):1867-74. Epub 2005 May 12.

32.
33.

A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch.

Rowley SD, Feng Z, Chen L, Holmberg L, Heimfeld S, MacLeod B, Bensinger WI.

Bone Marrow Transplant. 2003 Jun;31(11):1043-51.

PMID:
12774058
34.

Vaccinations against infectious diseases in hematopoietic stem cell transplant recipients.

Goldberg SL, Cicogna CE, Rowley SD, Pecora AL.

Oncology (Williston Park). 2003 Apr;17(4):539-54, 559; discussion 559-60, 564-5. Review.

35.

Treating refractory chronic graft-versus-host disease with extracorporeal photochemotherapy.

Bisaccia E, Palangio M, Gonzalez J, Adler KR, Rowley SD, Goldberg SL.

Bone Marrow Transplant. 2003 Feb;31(4):291-4.

PMID:
12621465
36.

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.

Goldberg SL, Madan RA, Rowley SD, Pecora AL, Hsu JW, Tantravahi R.

Blood. 2003 Jan 15;101(2):781. No abstract available.

37.

Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance.

Pecora AL, Lazarus HM, Jennis AA, Preti RA, Goldberg SL, Rowley SD, Cantwell S, Cooper BW, Copelan EA, Herzig RH, Meagher R, Kennedy MJ, Akard LR, Jansen J, Ross A, Prilutskaya M, Glassco J, Kahn D, Moss TJ.

Biol Blood Marrow Transplant. 2002;8(10):536-43.

38.

Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors.

Hübel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley SD, Chauncey TR, Bensinger WI, Boeckh M.

Transfusion. 2002 Nov;42(11):1414-21.

PMID:
12421213
39.

Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.

Hawkins DS, Felgenhauer J, Park J, Kreissman S, Thomson B, Douglas J, Rowley SD, Gooley T, Sanders JE, Pendergrass TW.

Cancer. 2002 Sep 15;95(6):1354-65.

40.

Current good manufacturing practices: application to the processing of hematopoietic cell components.

Rowley SD.

Cytotherapy. 2000;2(1):59-62. No abstract available.

PMID:
12042056
41.

Regulation of hematopoietic stem cell processing and transplantation.

Rowley SD.

Int J Hematol. 2002 Apr;75(3):237-45. Review.

PMID:
11999350
42.

Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

Sotomayor EM, Piantadosi S, Miller CB, Karp JE, Jones RJ, Rowley SD, Kaufmann SH, Braine H, Burke PJ, Gore SD.

Leuk Res. 2002 May;26(5):461-71.

PMID:
11916520
43.
44.

Trafficking of CD34+ cells into the peripheral circulation during collection of peripheral blood stem cells by apheresis.

Rowley SD, Yu J, Gooley T, Heimfeld S, Holmberg L, Maloney D, Bensinger WI.

Bone Marrow Transplant. 2001 Oct;28(7):649-56.

45.

Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs.

Rowley SD.

Bone Marrow Transplant. 2001 Aug;28(4):315-21. Review.

46.

Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation.

Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR.

Blood. 2001 May 1;97(9):2541-8. Erratum in: Blood 2001 Sep 1;98(5):1301.

47.

Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.

Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH; American Society of Clinical Oncology.

J Clin Oncol. 2001 Mar 1;19(5):1519-38.

PMID:
11230498
48.

Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components.

Rowley SD, Liang PS, Ulz L.

Bone Marrow Transplant. 2000 Oct;26(7):749-57.

49.

Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation.

Flowers ME, Leisenring W, Beach K, Riddell S, Radich JP, Higano CS, Rowley SD, Chauncey TR, Sanders JE, Anasetti C, Storb R, Wade J, Appelbaum FR, Martin P.

Biol Blood Marrow Transplant. 2000;6(3A):321-6.

PMID:
10905769
50.

Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection.

Yu J, Leisenring W, Fritschle W, Heimfeld S, Shulman H, Bensinger WI, Holmberg LA, Rowley SD.

Bone Marrow Transplant. 2000 Jun;25(11):1157-64.

Supplemental Content

Loading ...
Support Center